<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129113</url>
  </required_header>
  <id_info>
    <org_study_id>MAVMET</org_study_id>
    <nct_id>NCT03129113</nct_id>
  </id_info>
  <brief_title>Adding MAraViroc &amp;/or METformin for Hepatic Steatosis in People Living With HIV</brief_title>
  <acronym>MAVMET</acronym>
  <official_title>A Multicentre, 48 Week Randomised Controlled Factorial Trial of Adding Maraviroc and/or Metformin for Hepatic Steatosis in HIV-1-infected Adults on Combination Antiretroviral Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Free Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, phase IV, randomised, open-label, trial exploring adjunctive maraviroc&#xD;
      and/or metformin for liver steatosis over 48 weeks.&#xD;
&#xD;
      Sponsored by University College London Coordinated by MRC Clinical Trials Unit at UCL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a global epidemic of obesity and/or being overweight. Fatty liver disease associated&#xD;
      with overweight/obesity, can cause liver inflammation, which can lead to scarring of the&#xD;
      liver (cirrhosis), liver cancer and early death. It is predicted that fatty liver disease&#xD;
      will become the number one cause of liver cirrhosis in the next 20 years. There are no&#xD;
      effective treatments, except weight loss, which is rarely successful.&#xD;
&#xD;
      In HIV-infected individuals, antiretroviral therapy (ART) is very successful at maintaining&#xD;
      health long-term. However, despite this, data suggest that HIV-infected individuals are at&#xD;
      greater risk of developing fatty liver disease than the general population, even if they are&#xD;
      not overweight. Past exposure to some of the older, now obsolete, ART drugs, may have added&#xD;
      to this greater risk. What makes things more difficult is that fatty liver disease can be&#xD;
      'silent' with no symptoms or signs until quite advanced.&#xD;
&#xD;
      MAVMET is trying to find out if maraviroc (licensed anti-HIV drug) and metformin (licensed&#xD;
      for diabetes), given separately or in combination will reduce the amount of liver fat.&#xD;
&#xD;
      MAVMET participants are HIV-infected adult (aged at least 35), with HIV (but not hepatitis&#xD;
      B/C) for 5 years or more, on combination ART for at least 1 year, and likely - because of&#xD;
      abnormal liver tests and/or a large waist to have increased liver fat or already have a&#xD;
      confirmed diagnosis of fatty liver disease, on a previous scan or a liver biopsy.&#xD;
&#xD;
      Participants will continue on their current ART and be randomised (like the flip of a coin)&#xD;
      to receive 48 weeks of maraviroc (Arm A) or metformin (Arm B) or both drugs (Arm C) or no&#xD;
      additional drugs (Arm D). Participants have 7 clinic visits over 48 weeks to monitor progress&#xD;
      and 2 magnetic liver scans (MRI) (no radiation) at University College Hospital to measure&#xD;
      liver fat. Mortimer Market Centre participants can also have optional brain MRI at the&#xD;
      Institute of Neurology.&#xD;
&#xD;
      Patients can enrol at one of 3 sites: Mortimer Market Centre, St.Thomas's Hospital, King's&#xD;
      College Hospital, London.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">November 6, 2020</completion_date>
  <primary_completion_date type="Actual">November 5, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2 by 2 factorial randomisation to one of the 4 arms.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in percentage of liver fat as measured by MR PDFF between baseline and week 48.</measure>
    <time_frame>48 weeks</time_frame>
    <description>MR PDFF</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hepatic Steatosis</condition>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>maraviroc (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin (Arm B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>metformin 500mg BID p/o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maraviroc + metformin (Arm C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>maraviroc dosed BID p/o (dose adjusted depending on background combination antiretroviral therapy) PLUS metformin 500mg BID p/o.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no adjunctive therapy (Arm D)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no adjunctive therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <description>1:1:1:1 randomisation to one of four arms for 48 weeks</description>
    <arm_group_label>maraviroc (Arm A)</arm_group_label>
    <arm_group_label>maraviroc + metformin (Arm C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1:1:1:1 randomisation to one of four arms for 48 weeks</description>
    <arm_group_label>maraviroc + metformin (Arm C)</arm_group_label>
    <arm_group_label>metformin (Arm B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PATIENT INCLUSION CRITERIA&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Males or females ≥35 years of age&#xD;
&#xD;
          3. Chronic HIV-1-infection for ≥5 years&#xD;
&#xD;
          4. On combination antiretroviral therapy (cART) and with virological suppression (&lt;50&#xD;
             copies/mL) for ≥1 year&#xD;
&#xD;
          5. i) &gt;1 abnormal (above the upper limit) of LFTS (ALT or AST) in the last 2 years with&#xD;
             no other explanation (e.g. secondary syphilis) and/or ii) increased waist&#xD;
             circumference ≥94 cm (≥90cm if South Asian origin) in men, ≥80cm in women and/or iii)&#xD;
             a confirmed diagnosis of NAFLD on liver imaging (CT/MRI/ultrasound), FibroScan and/or&#xD;
             iv) liver biopsy confirmed diagnosis of NALFD&#xD;
&#xD;
          6. Females of child bearing potential (CBP) who agree to avoid pregnancy for the duration&#xD;
             of the trial&#xD;
&#xD;
          7. Able to comply with protocol requirements&#xD;
&#xD;
        PATIENT EXCLUSION CRITERIA&#xD;
&#xD;
          1. Co-infection with hepatitis B or C&#xD;
&#xD;
          2. Confirmed chronic liver disease from any other cause (e.g. hepatitis C, hepatitis B)&#xD;
&#xD;
          3. Daily intake of alcohol &gt;20g in women and &gt;30g in men&#xD;
&#xD;
          4. Current illicit drug use that in the opinion of the investigator would interfere with&#xD;
             patient's ability to comply with the protocol&#xD;
&#xD;
          5. On metformin or another biguanide agent;&#xD;
&#xD;
          6. Currently on maraviroc&#xD;
&#xD;
          7. Any contraindication to the receipt of maraviroc and/or metformin&#xD;
&#xD;
          8. Known B12 deficiency&#xD;
&#xD;
          9. Pregnant or breast feeding&#xD;
&#xD;
         10. Contraindication to MRI scanning&#xD;
&#xD;
         11. Peanut or soya allergy&#xD;
&#xD;
         12. eGFR &lt;60 ml/min/1.73m2&#xD;
&#xD;
         13. ALT ≥10 x ULN&#xD;
&#xD;
         14. History of cardiovascular (ischaemic heart disease) or cerebrovascular disease.&#xD;
&#xD;
         15. Any other condition that in the opinion of the investigator would not make the patient&#xD;
             suitable for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Pett</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1FR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Mortimer Market Centre</name>
      <address>
        <city>London</city>
        <zip>WC1E 6JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 21, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College, London</investigator_affiliation>
    <investigator_full_name>ADAM CURSLEY</investigator_full_name>
    <investigator_title>Trial Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

